Skip to main content

Table 3 Risk ratio (95% CI) of specific adverse effects between different treatment groups

From: Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: a meta-analysis of randomized controlled trials

Comparison GI AE CV AE CNS AE MU AE Infection Skin AE Others
G vs PBO 0.99(0.79, 1.23) NA 0.72(0.46, 1.10) 1.52(0.88, 2.63) 1.07(0.50, 2.32) 0.80(0.38, 1.68) 1.21(0.98, 1.48)
C vs PBO 0.35(0.14, 0.87) 1.13(0.45, 2.84) 0.79(0.37, 1.67) NA 0.98(0.72, 1.34) 1.00(0.41, 2.45) NA
G + C vs PBO 2.79(0.30, 26.00) NA 1.86(0.36, 9.74) 2.79(0.30, 26.00) 2.79(0.12, 67.10) NA 4.66(0.23, 94.79)
Overall 0.92(0.74, 1.13) 1.13(0.45, 2.84) 0.77(0.54, 1.11) 1.58(0.93, 2.70) 1.01(0.76, 1.35) 0.88(0.50, 1.55) 1.22(1.00, 1.50)
  1. G glucosamine, C chondroitin, G + C glucosamine + chondroitin, PBO placebo, NA not available, GI gastrointestinal, CV cardiovascular, CNS central nervous system, MU musculoskeletal